Search Within

Malin Lisa Hultcrantz

Formats
  1. Meeting Abstract (178)
  2. Journal Article (70)
  3. Research Letter (10)
  4. Guidelines (6)
  5. Correspondence (3)
  6. Review (3)
  7. Book Section (1)
Groups
  1. Center for Hematologic Malignancies (271)
  2. Department of Medicine (271)
  3. Hematologic Malignancies, Division of (271)
  4. Myeloma (271)
  5. Sloan Kettering Institute Postdocs (271)
  6. Hematologic Malignancies Research (188)

More Groups

People
  1. Sham Mailankody (157)
  2. Neha Korde (154)
  3. Alexander Lesokhin (149)
  4. Hani Hassoun (143)
  5. Urvi Shah (134)
  6. Sergio Giralt (128)

More People

Years
  1. 2025 (12)
  2. 2024 (46)
  3. 2023 (51)
  4. 2022 (52)
  5. 2021 (30)
  6. 2020 (26)

More Years

Publications
  1. Blood (104)
  2. Clinical Lymphoma, Myeloma and Leukemia (50)
  3. Journal of Clinical Oncology (17)
  4. Blood Cancer Journal (14)
  5. Haematologica (10)
  6. Blood Advances (7)

More Publications

Publishers
  1. American Society of Hematology (111)
  2. Elsevier Inc. (56)
  3. Nature Publishing Group (22)
  4. American Society of Clinical Oncology (17)
  5. Ferrata Storti Foundation (10)
  6. American Association for Cancer Research (6)

More Publishers

Results (271)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Transient M-proteins: Epidemiology, causes, and the impact of mass spectrometry: The iStopMM study
    Meeting Abstract

    Palmason, R.; Berlanga, O.; Sigurdsson, J. K.; Rögnvaldsson, S.; Thorsteinsdottir, S.; Ekberg, S.; Crowther, M.; Levy, M.; Reed, E. R.; Þórir Oskarsson, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Maintenance Therapy Cessation for Sustained MRD Negative Multiple Myeloma Patients
    Meeting Abstract

    Korde, N.; Diamond, B.; Burge, M.; Hassoun, H.; Landau, H.; Hultcrantz, M.; Mailankody, S.; Maclachlan, K. H.; Shah, U. A.; Derkach, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Carfilzomib, lenalidomide and dexamethasone (KRd) vs bortezomib, lenalidomide, and dexamethasone (VRd) as induction therapy in newly diagnosed high-risk multiple myeloma
    Meeting Abstract

    Tan, C.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Patel, D.; Maclachlan, K. H.; Lahoud, O. B.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Individualized treatment-adjusted risk stratification in newly diagnosed multiple myeloma
    Meeting Abstract

    Maura, F.; Rajanna, A. R.; Derkach, A.; Ziccheddu, B.; Weinhold, N.; Maclachlan, K. H.; Diamond, B.; Davies, F. E.; Boyle, E.; Walker, B. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Genomic determinants of resistance in newly diagnosed multiple myeloma treated with targeted-immunotherapy
    Meeting Abstract

    Maura, F.; Boyle, E.; Coffey, D.; Maclachlan, K. H.; Diamond, B.; Blaney, P.; Gagler, D.; Ziccheddu, B.; Ghamlouch, H.; Wang, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • SARS-CoV-2 vaccinations do not lead to progression of monoclonal gammopathy of undetermined significance: Results from the population-based iStopMM screening study
    Meeting Abstract

    Palmason, R.; Eythorsson, E.; Rögnvaldsson, S.; Thorsteinsdottir, S.; Ekberg, S.; Crowther, M.; Reed, E. R.; Oskarsson, J. Þ.; Sigurdardottir, G. A.; Aspelund, T.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Prevalence of MGUS is high in the iStopMM study but the prevalence of IgA MGUS does not increase with age in the way other immunoglobulin subtypes do
    Meeting Abstract

    Love, T. J.; Rögnvaldsson, S.; Thorsteinsdottir, S.; Aspelund, T.; Reed, E. R.; Vidarsson, B.; Onundarson, P. T.; Agnarsson, B. A.; Sigurdardottir, M.; Thorsteinsdottir, I.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Predicting the need for upfront bone marrow sampling in individuals with MGUS: Derivation of a multivariable prediction model using the prospective population-based iStopMM cohort
    Meeting Abstract

    Eythorsson, E.; Rögnvaldsson, S.; Thorsteinsdóttir, S.; Reed, E. R.; Sigurdardóttir, G. Á.; Vidarsson, B.; Onundarson, P. T.; Agnarsson, B.; Sigurdardóttir, M.; Ólafsson, I.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Fc-mediated antibody effector function, inflammation resolution and oligoclonality on TCR rearrangements predict sustained MRD negativity in newly diagnosed multiple myeloma treated with immunotherapy regimens
    Meeting Abstract

    Boyle, E. M.; Maura, F.; Coffey, D.; Maclachlan, K. H.; Diamond, B.; Ghamlouch, H.; Gagler, D.; Blaney, P.; Ziccheddu, B.; Wang, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Stem cell autograft minimal residual disease negativity improves outcomes after autotransplant for multiple myeloma
    Meeting Abstract

    Nishimura, N.; Brown, S.; Devlin, S. M.; Dahi, P. B.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Hassoun, H.; Hultcrantz, M.; more...
    Blood (2022)

    Fulltext@MSK | Save